Fatty acid synthase expression in osteosarcoma and its correlation with pulmonary metastasis

Oncology Letters

Volumn 4, Issue 5, 2012, Pages 878-882

  Liu, Zhi Li ^a   Wang, Gao ^a   Peng, Ai Fen ^b   Luo, Qing Feng ^c   Zhou, Yang ^a   Huang, Shan Hu ^a  

^a NANCHANG UNIVERSITY   (China)

^b JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c People's Hospital of Jiangxi Province   (China)

Author keywords

Fatty acid synthase; Immunohistochemical; Metastasis; Osteosarcoma

Indexed keywords

FATTY ACID SYNTHASE; KI 67 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BONE METASTASIS; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MAJOR CLINICAL STUDY; OSTEOSARCOMA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STAINING;

EID: 84866065752     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.862     Document Type: Article

References (30)

1. Longhi A, Errani C, De Paolis M, et al: Primary bone OS in the pediatric age: State of the art. Cancer Treatment Reviews 32: 423-436, 2006.
2. Mckenna R, Schwinn CP, Soong KY, et al: Sarcomata of the osteogenic series (osteosarcoma, fibrosarcoma, chondrosarcoma, parosteal osteogenic sarcoma, and sarcomata arising in abnormal bone) an analysis of 552 cases. J Bone Joint Surg 48: 1-26, 1966.
3. Iwamoto Y, Tanaka K, Isu K, et al: Multiinstitutional phase II study of neoadjuvant chemotherapy for OS (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci 14: 397-404, 2009.
4. Meyers PA, Schwartz CL, Krailo M, et al: OS: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23: 2004-2011, 2005.
5. Jawad MU, Cheung MC, et al: Osteosarcoma: improvement in survival limited to high-grade patients only. J Cancer Res Clin Oncol 137: 597-607, 2011.
6. Mialou V, Philip T, Kalifa C, et al: Metastatic OS at diagnosis: prognostic factors and long-term outcome-the French pediatric experience. Cancer 104: 1100-1109, 2005.
7. Hegyi M, Semsei AF, Jakab Z, et al: Good prognosis of localized OS in young patients treated with limb-salvage surgery and chemotherapy. Pediatr Blood Cancer 57: 415-422, 2011.
8. Stokkel MP, Linthorst MF, Borm JJ, et al: A reassessment of bone scintigraphy and commonly tested pretreatment biochemical parameters in newly diagnosed osteosarcoma. J Cancer Res Clin Oncol 128: 393-399, 2002.
9. Alo PL, Amini M, Piro F, et al: Immunohistochemical expression and prognostic significance of fatty acid synthase in pancreatic carcinoma. Anticancer Res 27: 2523-2527, 2007.
10. Kusakabe T, Nashimoto A, Honma K, et al: Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach. Histopathology 40: 71-79, 2002.
11. Walter K, Hong SM, Nyhan S, et al: Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidemiol Biomarkers Prev 18: 2380-2385, 2009.
12. Okawa Y, Hideshima T, Ikeda H, et al: Fatty acid synthase is a novel therapeutic target in multiple myeloma. British Journal of Haematology 141: 659-671, 2008.
13. Migita T, Ruiz S, Fornari A, et al: Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 101: 519-532, 2009.
14. Yan S, Kefeng W and Sheng SY: Expression of fatty acid synthase in bladder transitional cell carcinoma and its significance. China Oncology 17: 395-397, 2007.
15. Silva SD, Cunha IW, Younes RN, et al: ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas. Oral Dis 16: 774-780, 2010.
16. Crispino P, Alò PL, Rivera M, et al: Evaluation of fatty acid synthase expressionin oesophageal mucosa of patients with oesophagitis, Barrett's oesophagus and adenocarcinoma. J Cancer Res Clin Oncol 135: 1533-1541, 2009.
17. Orita H, Coulter J, Tully E, et al: Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumors. Clin Cancer Res 14: 2458-2464, 2008.
18. Coleman DT, Bigelow R and Cardelli JA: Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal lysosomal degradation. Mol Cancer Ther 8: 214-224, 2009.
19. Carvalho MA, Zecchin KG, Seguin F, et al: Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model. Int J Cancer 123: 2557-2565, 2008.
20. Murata S, Yanagisawa K, Fukunaga K, et al: Fatty acid synthase inhibitor cerulenin suppresses liver metastasis of colon cancer in mice. Cancer Sci 101: 1861-1865, 2010.
21. Lin C, Ming LW, Bao LF, et al: Expressions of P21(WAF1) protein, CNA and Ki-67 and their significance in osteosarcoma. China Oncology 11: 109-112, 2001.
22. Yeh CS, Wang JY, Cheng TL, et al: Fatty acid metabolism pathway play an important role in carcinogenesis of human colorectal cancers by Microarray Bioinformatics analysis. Cancer Lett 233: 297-308, 2006.
23. Flavin R, Peluso S, Nguyen PL and Loda M: Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 6: 551-562, 2012.
24. Takahiro T, Shinichi K and Toshimitsu S: Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas. Clin Cancer Res 9: 2204-2212, 2003.
25. Kusakabe T, Maeda M, Hoshi N, et al: Fatty acid synthase is expressed mainly in adult hormone-sensitive cells or cells with high lipid metabolism and in proliferating fetal cells. J Histochem Cytochem 48: 613-622, 2000.
26. Menendez JA and Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7: 763-777, 2007.
27. Rossi S, Ou W, Tang D, et al: Gastrointestinal stromal tumours overexpress fatty acid synthase. J Pathol 209: 369-375, 2006.
28. Silva SD, Perez DE, Nishimoto IN, et al: Fatty acid synthase expression in squamous cell carcinoma of the tongue: clinicopathological findings. Oral Dis 14: 376-382, 2008.
29. Alò PL, Visca P, Framarino ML, et al: Immunohistochemical study of fatty acid synthase in ovarian neoplasms. Oncol Rep 7: 1383-1388, 2000.
30. Selvendiran K, Ahmed S, Dayton A, et al: HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase. Mol Cancer Res 8: 1188-1197, 2010.